1036499-68-9

Upstream product

• 1439933-35-3 methyl 1-((4-bromophenyl)methyl)-1,3-benzodiazole-5-carboxylate 
• 1304613-72-6 methyl 3-amino-4-((4-bromobenzyl)amino)benzoate 
• 954231-79-9 methyl 4-((4-bromobenzyl)amino)-3-nitrobenzoate 
• 3959-07-7 4-Bromobenzylamine 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 

Downstream Products

• 1439933-36-4 (S)-1-(4-bromobenzyl)-N-(1-(3-isopropylphenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide 
• 1439933-37-5 (S)-N-(1-(3-isopropylphenyl)ethyl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-benzo[d]imidazole-5-carboxamide 
• 1439933-38-6 (S)-methyl 3-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)picolinate 
• 1439933-15-9 (S)-3-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)picolinic acid 

Relevant academic research and scientific papers

N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.